Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease (Q41735095)

8 October 2017

1 reference

title

Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease (English)

1 reference

8 October 2017

Cooper DS

1 reference

8 October 2017

publication date

1 March 1998

1 reference

Endocrinology and Metabolism Clinics of North America

8 October 2017

published in

1 reference

8 October 2017

1 reference

8 October 2017

1 reference

8 October 2017

page(s)

225-247

1 reference

Influence of iodine intake after treatment with antithyroid drugs.

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid Drugs and Graves' Disease: A Prospective Randomized Evaluation of the Efficacy of Treatment Duration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Comparison of propranolol and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Thyroid Storm Treatment With Blood Exchange and Plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Rapid preoperative preparation in hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmö during the period 1970-1974

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Early remission in thyrotoxicosis produced by short courses of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Follow-Up Comparison of Short-TermVersus1-Year Antithyroid Drug Therapy for the Thyrotoxicosis of Graves' Disease*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Thyrotropin results in euthyroid patients with a past history of hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

1 reference

7 January 2021

Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Which anti-thyroid drug?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drugs: to breast-feed or not to breast-feed

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Studies of propylthiouracil using a newly developed radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Acute Effects of Propylthiouracil (PTU) on Thyroidal Iodide Organification and Peripheral Iodothyronine Deiodination: Correlation with Serum PTU Levels Measured by Radioimmunoassay*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Effect of pretreatment with methylthiouracil on results of I-131 therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Lithium treatment in amiodarone-induced thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Serum Thyroxine and Triiodothyronine Concentrations During Iodide Treatment of Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Preferential inhibition of thyroxine and 3,5,3'-triiodothyronine formation by propylthiouracil and methylmercaptoimidazole in thyroid peroxidase-catalyzed iodination of thyroglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole Has No Dose-Related Effect on the Serum Concentrations of Soluble Class I Major Histocompatibility Complex Antigens, Soluble Interleukin-2 Receptor, and β2-Microglobulin in Patients with Graves' Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Prediction of the course of Graves' disease after medical antithyroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Propranolol in the surgical treatment of hyperthyroidism, including severely thyrotoxic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Iodide-induced thyrotoxicosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Liver tests in hyperthyroidism: effect of antithyroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Late onset hypothyroidism after subtotal thyroidectomy for hyperthyroidism: implications for long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Long-term outcome of hyperthyroidism treated with antithyroid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Short‐term treatment of Graves' disease with methimazole in high versus low doses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Post-thyroidectomy thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Reemergence of Thyroidectomy as Treatment for Graves’ Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Lithium carbonate in the treatment of thyrotoxicosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Spontaneous hypothyroidism after antithyroid treatment of hyperthyroid Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Thyroxine 5'-deiodinase activity of rat kidney: observations on activation by thiols and inhibition by propylthiouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A clinical guide to the management of Graves' disease with radioactive iodine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Long-term follow-up of patients with Grave's disease treated by subtotal thyroidectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Treatment of hyperthyroidism with a small single daily dose of methimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Carbimazole and the Autoimmune Response in Graves' Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Maternal hyperthyroidism and congenital malformation in the offspring

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole: an alternative route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A Follow-Up Study of 85 Patients with Graves&rsquo; Disease in Remission Who Developed Undetectahle Serum Thyroid-Stimulating Hormone Concentrations Using Sensitive TSH Assays

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Single Daily Dose of Methimazole Compared to Every 8 Hours Propylthiouracil in the Treatment of Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Higher than conventional doses of carbimazole in the treatment of thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Hyperthyroidism and hypothyroidism complicating the treatment of thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The influence of methimazole on thyroglobulin-induced autoimmune thyroiditis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Comparison of Effects of High and Low Dosage Regimens of Antithyroid Drugs in the Management of Graves’ Hyperthyroidism*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole and Serum Thyroid Hormone Concentrations in Hyperthyroid Patients: Effects of Single and Multiple Daily Doses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

COMPARISON OF METHIMAZOLE, METHIMAZOLE AND SODIUM IPODATE, AND METHIMAZOLE AND SATURATED SOLUTION OF POTASSIUM IODIDE IN THE EARLY TREATMENT OF HYPERTHYROID GRAVES’DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The antithyroid arthritis syndrome reviewed

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Treatment of hyperthyroidism with sodium ipodate (oragrafin) in addition to propylthiouracil and propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Long-term Antithyroid Treatment in Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Current Trends in the Management of Graves' Disease*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Adjunctive cholestyramine therapy for thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A reexamination of the proposed inactivation of thyroid peroxidase in the rat thyroid by propylthiouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Metabolism of 35S- and 14C-labeled propylthiouracil in a model in vitro system containing thyroid peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Methimazole, carbimazole, and congenital skin defects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Hepatotoxicity from antithyroid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Evidence That the Immunosuppressive Effects of Antithyroid Drugs Are Mediated through Actions on the Thyroid Cell, Modulating Thyrocyte-Immunocyte Signaling: A Review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Rectal administration of propylthiouracil in the treatment of Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Differences and Similarities in the Diagnosis and Treatment of Graves' Disease in Europe, Japan, and The United States

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Has the use of antithyroid drugs for Graves' disease become obsolete?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The Immunomodulatory Effects of Antithyroid Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves’ disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Factors influencing the outcome of thyrostatic drug therapy in Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

Hypothyroidism as a Late Sequela in Patients with Graves' Disease Treated with Antithyroid Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

The binding of thioureylene compounds to human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970308-X

7 January 2021

10.1016/S0889-8529(05)70308-X

Identifiers

DOI

1 reference

8 October 2017

1 reference